


Figure 2. Analysis of Progression-Free Survival



No. at risk	
SAbR plus maintenance	14      12      6      3      1
Maintenance only	15      8      1      1      1

Log-rank testing reveals a statistically significant benefit in progression-free survival for SAbR-plus-maintenance chemotherapy (hazard ratio, 0.304; 95% CI, 0.113-0.815;  $P = .01$ ). SAbR indicates stereotactic ablative radiotherapy.